Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 475207-59-1 | 產品號碼: N1229
Sorafenib Tosylate
×
![]()
×
纯度/分析方法: >98.0%(T)(HPLC)
別名
- 4-[4-[3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido]phenoxy]-N-methylpicolinamide 4-Methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamamido]phenoxy]-N-methyl-2-pyridinecarboxamide 4-Methylbenzenesulfonate
文件：
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | N1229 |
| 純度/分析方法 | >98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__2__1H__1__6ClF__3N__4O__3.C__7H__8O__3S = 637.03 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Refrigerated (0-10°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Air Sensitive,Heat Sensitive |
| 包裝和容器 | 1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 475207-59-1 |
| Reaxys-RN | 11116227 |
| MDL編號 | MFCD08235032 |
產品規格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 222.0 to 226.0 °C |
| NMR | confirm to structure |
性質
| 熔點 | 224 °C |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
相關法規
| RTECS # | US4588880 |
運輸資料
| HS編碼* | 2933.39-000 |
Application
Sorafenib Tosylate: An Orally Active Multikinase Inhibitor
Sorafenib tosylate (BAY 43-9006) is an orally active multikinase inhibitor that decrease tumor cell proliferation. There are reports that sorafenib is shown to inhibits cell surface tyrosine kinase receptors (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß: platelet-derived growth factor receptor-β) and downstream intracellular serine/threonine kinases (c-CRAF, BRAF and mutant BRAF) in vitro.1-3) Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis.4,5) In clinical, sorafenib tosylate is used for the treatment of renal cell carcinoma and hepatocellular carcinoma. (The product is for research purpose only.)
References
- 1) BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- 2) Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
- 3) BAY 43-9006 Inhibition of Oncogenic RET Mutants
- F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, M. Santoro, J. Natl. Cancer Inst. 2006, 98, 326.
- 4) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (a review)
- 5) Sorafenib: a review of its use in advanced hepatocellular carcinoma
- 6) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。